Search Results

Tectonic Therapeutic, Inc. today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced the completion of its previously announced merger with AVROBIO, Inc.

Tectonic Therapeutic, Inc. today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March.

AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).